NEUROCRINE BIOSCIENCES INC (NBIX)

137.52 0 (0%)

As of 2025-10-16 15:10:05 EST

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

Traded asNasdaq: NBIX
ISINUS64125C1099
CIK0000914475
LEI549300FECER0XBN49756
EIN330525145
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOKyle Gano
Employees1,350
Fiscal Year End1231
Address6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
Phone(858) 617-7600
Websitehttp://neurocrine.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
NBIXNEUROCRINE BIOSCIENCES INC2025-10-16 15:10:05137.5200
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
NBIX0000914475NEUROCRINE BIOSCIENCES INCUS64125C1099549300FECER0XBN49756330525145Nasdaq2836Biological Products, (No Diagnostic Substances)1231DE6027 EDGEWOOD BEND COURTSAN DIEGOCA92130UNITED STATESUS(858) 617-76006027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 921306027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130—Biotechnology1992Kyle Gano1,350http://neurocrine.com10,500,000,00099,000,00099,181,510Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).2025-10-10 19:40:02
This is a preview of the latest data. Subscribe to access the full data.
NBIX Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
NBIX Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202410,500,000,0002,600,000,00032.911499,703,527196,0370.197
20237,900,000,000-197,146,859-2.434899,507,4902,919,5793.0227
20228,097,146,859-1,008,109,519-11.071796,587,9111,345,2281.4124
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Jude Onyia, Ph.D.Chief Scientific Officer2023638,250351,0382,625,124—233,7807,223,216
Eiry W. RobertsChief Medical Officer2023660,348399,5112,125,112—63,8525,873,847
Kevin C. Gorman, Ph.D.Chief Executive Officer2023946,0001,040,6007,021,386—64,03615,750,812
Matthew C. AbernethyChief Financial Officer2023646,061355,3351,812,563—56,3876,057,882
Eiry W. RobertsChief Medical Officer2022631,912345,1822,075,144—57,9865,735,281
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20241,800
20231,400
2020845
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue2,355,300,0001,887,100,0001,488,700,000
Cost Of Revenue34,000,00039,700,00023,200,000
Gross Profit———
Research And Development Expenses731,100,000565,000,000463,800,000
General And Administrative Expenses1,007,200,000887,600,000752,700,000
Operating Expenses1,784,800,0001,636,200,0001,239,700,000
Operating Income570,500,000250,900,000249,000,000
Net Income341,300,000249,700,000154,500,000
Earnings Per Share Basic3.42.561.61
Earnings Per Share Diluted3.292.471.56
Weighted Average Shares Outstanding Basic100,400,00097,700,00095,800,000
Weighted Average Shares Outstanding Diluted103,700,000101,000,00098,900,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents233,000,000251,100,000262,900,000
Marketable Securities Current843,100,000780,500,000726,400,000
Accounts Receivable479,100,000439,300,000350,000,000
Inventories57,400,00038,300,00035,100,000
Non Trade Receivables———
Other Assets Current112,100,00097,800,00079,100,000
Total Assets Current1,724,700,0001,607,000,0001,453,500,000
Marketable Securities Non Current739,500,000687,500,000299,400,000
Property Plant And Equipment82,600,00070,800,00058,600,000
Other Assets Non Current15,500,00049,600,00025,000,000
Total Assets Non Current1,994,000,0001,644,400,000915,200,000
Total Assets3,718,700,0003,251,400,0002,368,700,000
Accounts Payable461,600,000448,800,000347,600,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current46,100,00035,900,00020,700,000
Total Liabilities Current507,700,000654,800,000537,700,000
Long Term Debt——0
Other Liabilities Non Current166,200,000106,300,00029,700,000
Total Liabilities Non Current621,300,000364,600,000123,200,000
Total Liabilities1,129,000,0001,019,400,000660,900,000
Common Stock100,000100,000100,000
Retained Earnings29,200,000-157,100,000-406,800,000
Accumulated Other Comprehensive Income5,800,0007,000,000-7,900,000
Total Shareholders Equity2,589,700,0002,232,000,0001,707,800,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization23,500,00017,800,00015,100,000
Share Based Compensation Expense195,500,000194,300,000173,100,000
Other Non Cash Income Expense——0
Change In Accounts Receivable39,800,00089,300,000162,200,000
Change In Inventories19,100,000-5,400,0002,600,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable29,000,00064,300,000114,600,000
Change In Other Liabilities-10,700,000-47,800,000—
Cash From Operating Activities595,400,000389,900,000339,400,000
Purchases Of Marketable Securities1,056,100,0001,379,900,000621,200,000
Sales Of Marketable Securities967,500,000972,400,000511,000,000
Acquisition Of Property Plant And Equipment38,200,00028,300,00016,500,000
Acquisition Of Business0042,700,000
Other Investing Activities———
Cash From Investing Activities-126,800,000-467,100,000-177,100,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock122,100,00065,300,00044,700,000
Repurchase Of Common Stock300,000,000——
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities-486,700,00065,300,000-234,300,000
Change In Cash-18,100,000-11,600,000-73,300,000
Cash At End Of Period233,000,000251,100,000262,900,000
Income Taxes Paid217,500,00051,500,00014,400,000
Interest Paid1,600,0003,800,0006,600,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share3.42.561.61
Price To Earnings Ratio40.147151.468874.1863
Earnings Growth Rate32.812559.006269.4737
Price Earnings To Growth Ratio1.22350.87231.0678
Book Value Per Share25.793822.845417.8267
Price To Book Ratio5.2925.76756.7001
Ebitda582,300,000323,600,000191,100,000
Enterprise Value——11,179,452,000
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio——0
Capital Expenditures35,300,00030,000,00015,100,000
Free Cash Flow560,100,000359,900,000324,300,000
Return On Equity0.13180.11190.0905
One Year Beta0.54520.42410.5324
Three Year Beta0.50670.54330.6813
Five Year Beta0.65120.6990.7686
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Onyia JudeChief Scientific Officer2025-09-031,470D13,703
SHERWIN STEPHEN ADirector2025-09-021,000D12,542
GORMAN KEVIN CHARLESDirector2025-08-07106,322A620,918
GORMAN KEVIN CHARLESDirector2025-08-07106,322D514,596
GORMAN KEVIN CHARLESDirector2025-08-07106,322D0
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Lisa McClain2025-08-13MI09Sale (Partial)2025-06-17Spouse$1,001 - $15,000
Lisa McClain2025-08-13MI09Purchase2025-06-11Spouse$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Capital Advisors, Ltd. LLC2025-09-301,0004250
RICE HALL JAMES & ASSOCIATES, LLC2025-09-3013,962,89799,465140.38
BURNEY CO/2025-09-304,046,45428,825140.38
Blue Trust, Inc.2025-09-301,2639140.3333
Avanza Fonder AB2025-09-30525,1623,741140.3801
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
TRUST FOR PROFESSIONAL MANAGERS2025-08-31Column Mid Cap FundCFMCX2,846397,301.60.0399
Pacer Funds Trust2025-07-31Pacer Trendpilot US Mid Cap ETFPTMC14,0441,800,862.120.4298
AMERICAN PENSION INVESTORS TRUST2025-07-31Institutional ClassAPGRX2,250288,517.50.3119
AMERICAN PENSION INVESTORS TRUST2025-07-31Class A SharesAFGGX2,250288,517.50.3119
AMERICAN PENSION INVESTORS TRUST2025-07-31Class L SharesAPITX2,250288,517.50.3119
This is a preview of the latest data. Subscribe to access the full data.